These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 26807589)

  • 1. A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.
    Likanonsakul S; Suntisuklappon B; Nitiyanontakij R; Prasithsirikul W; Nakayama EE; Shioda T; Sangsajja C
    PLoS One; 2016; 11(1):e0147724. PubMed ID: 26807589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients.
    Salvaggio SE; Giacomelli A; Falvella FS; Oreni ML; Meraviglia P; Atzori C; Clementi EGI; Galli M; Rusconi S
    BMC Infect Dis; 2017 Jun; 17(1):396. PubMed ID: 28583112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.
    Rodríguez-Nóvoa S; Labarga P; Soriano V; Egan D; Albalater M; Morello J; Cuenca L; González-Pardo G; Khoo S; Back D; Owen A
    Clin Infect Dis; 2009 Jun; 48(11):e108-16. PubMed ID: 19400747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study.
    Nishijima T; Komatsu H; Higasa K; Takano M; Tsuchiya K; Hayashida T; Oka S; Gatanaga H
    Clin Infect Dis; 2012 Dec; 55(11):1558-67. PubMed ID: 22955427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study.
    Nishijima T; Hayashida T; Kurosawa T; Tanaka N; Oka S; Gatanaga H
    PLoS One; 2015; 10(11):e0141931. PubMed ID: 26535588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and methods of the prevalence and pharmacogenomics of tenofovir nephrotoxicity in HIV-positive adults in south-western Nigeria study.
    Hassan MO; Duarte R; Mabayoje VO; Dickens C; Lasisi AO; Naicker S
    BMC Nephrol; 2020 Oct; 21(1):436. PubMed ID: 33066744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy.
    Nishijima T; Kurosawa T; Tanaka N; Kawasaki Y; Kikuchi Y; Oka S; Gatanaga H
    AIDS; 2016 Jun; 30(10):1563-71. PubMed ID: 26919734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms associated with renal adverse effects of antiretroviral therapy in a Southern Brazilian HIV cohort.
    da Rocha IM; Gasparotto AS; Lazzaretti RK; Notti RK; Sprinz E; Mattevi VS
    Pharmacogenet Genomics; 2015 Nov; 25(11):541-7. PubMed ID: 26287941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
    Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Sungkanuparph S
    J Antimicrob Chemother; 2014 Aug; 69(8):2195-201. PubMed ID: 24788661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.
    Izzedine H; Hulot JS; Villard E; Goyenvalle C; Dominguez S; Ghosn J; Valantin MA; Lechat P; Deray AG
    J Infect Dis; 2006 Dec; 194(11):1481-91. PubMed ID: 17083032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued.
    Nishijima T; Mutoh Y; Kawasaki Y; Tomonari K; Kikuchi Y; Gatanaga H; Oka S;
    AIDS; 2018 Jan; 32(2):179-188. PubMed ID: 29028660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients.
    Cusato J; Calcagno A; Marinaro L; Avataneo V; DʹAvolio A; Di Perri G; Bonora S
    Pharmacogenomics J; 2020 Apr; 20(2):202-212. PubMed ID: 31619748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal function in HIV/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life setting.
    Milazzo L; Gervasoni C; Falvella FS; Cattaneo D; Mazzali C; Ronzi P; Binda F; Cheli S; Sollima S; Antinori S
    Clin Exp Pharmacol Physiol; 2017 Feb; 44(2):191-196. PubMed ID: 27809359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic determinants of tenofovir diphosphate and lamivudine triphosphate concentrations in people with HIV/HBV coinfection.
    Bae J; Tantawy M; Gong Y; Langaee T; Lartey M; Ganu V; Tachi K; Ojewale O; Obo-Akwa A; Boamah I; Bushman LR; Ellison L; Yang H; Anderson PL; Kwara A
    Antimicrob Agents Chemother; 2024 Sep; 68(9):e0054924. PubMed ID: 39078131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Highly Active Antiretroviral Therapy on Renal Function and Renal Phosphate Handling in African Adults with Advanced HIV and CKD.
    Adedeji TA; Adebisi SA; Adedeji NO; Biliaminu SA; Olanrewaju TO
    Infect Disord Drug Targets; 2019; 19(1):88-100. PubMed ID: 30027856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief Report: Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection.
    Archampong T; Ojewale O; Bears K; Chen Y; Lartey M; Sagoe KW; Obo-Akwa A; Gong Y; Langaee T; Kwara A
    J Acquir Immune Defic Syndr; 2019 Dec; 82(4):421-425. PubMed ID: 31335591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Prolonged Administration of Tenofovir Disoproxil Fumarate-Containing Antiviral Regimen on Renal Function in Low-Risk of Kidney Injury HIV Patients.
    Yuan Y; He S; Liu H; He Y; Zhou R; Yao Y; Yin K; Lyu C
    J Clin Pharmacol; 2024 May; 64(5):626-633. PubMed ID: 38323669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes.
    Giacomet V; Cattaneo D; Viganò A; Nannini P; Manfredini V; Ramponi G; Clementi E; Zuccotti GV
    Pediatr Infect Dis J; 2013 Oct; 32(10):e403-5. PubMed ID: 24067562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
    Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M;
    Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.